Medix Spółka z Ograniczoną Odpowiedzialnością (KRS 0000282959, NIP 5932178934) is a Polish company, headquartered in Łódź, Łódzkie voivodeship. MEDIX operates in: Dispensing chemist in specialised stores (PKD 47.73.Z). Industry: Retail trade. The company has been listed in the National Court Register since June 15, 2007. MEDIX's most recently reported net revenue was 56.0 M PLN for 2025.
Negative equity
Negative equity in 3 of 8 available reporting years.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Medix
Identity
- Name
- Medix Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- June 15, 2007
- Registry status as of
- June 26, 2026
- Latest entry
- June 26, 2026
- Founding act
- AKT NOTARIALNY Z DNIA 20.09.2024R., REP. A NR 3945/2024, NOTARIUSZ BARTŁOMIEJ JANICKI, KANCELARIA NOTARIALNA W ALEKSANDR…
Articles of association history (4)
- UMOWA SPÓŁKI - AKT NOTARIALNY Z DNIA 11 CZERWCA 2007 ROKU, NOTARIUSZ JOLANTA CEJROWSKA, REP.A NR 3529/2007, KANCELARIA NOTARIALNA W TCZEWIE PRZY ULICY KOŚCIUSZKI 8/1.
- AKT NOTARIALNY Z DNIA 30 LISTOPADA 2009 ROKU REP.A 9654/2009 NOTARIUSZ JOLANTA CEJROWSKA KANCELARIA NOTARIALNA W TCZEWIE, 83-110 TCZEW UL.KOŚCIUSZKI 8/1, ZMIENIONO TREŚĆ PARAGRAFU 6 UST.1 ORAZ UCHWALONO TEKST JEDNOLITY UMOWY SPÓŁKI.
- AKTEM NOTARIALNYM Z DNIA 5 LUTEGO 2020R., REP. A NR 281/2020, SPORZĄDZONYM PRZEZ NOTARIUSZA PIOTRA KRÓLA, KANCELARIA NOTARIALNA W ŁODZI PRZY UL. ŻWIRKI NR 19, ZMIENIONO §7 UST.3, §14 UST.3, §21 UMOWY SPÓŁKI.
- September 20, 2024: AKT NOTARIALNY Z DNIA 20.09.2024R., REP. A NR 3945/2024, NOTARIUSZ BARTŁOMIEJ JANICKI, KANCELARIA NOTARIALNA W ALEKSANDROWIE ŁÓDZKIM, UCHYLONO DOTYCHCZASOWĄ TREŚĆ UMOWY SPÓŁKI I PRZYJĘTO UMOWĘ SPÓŁKI W NOWYM BRZMIENIU
Activities
Main activity
47.73.ZDispensing chemist in specialised stores
Other activities
Address and contact
- Address
- UL. KINGA C. GILLETTE, 11, 94-406, ŁÓDŹ, POLSKA
- Voivodeship
- ŁÓDZKIE
- District
- ŁÓDŹ
- Not disclosed in the registry
- Website
- WWW.APTEKASAR.HOME.PL/MEDIXOGLOSZENIA
- E-delivery address
- Not disclosed in the registry
Risk and payment profile - Medix
Credibility rating
15.8 / 100
Very poor credibility
Insolvency risk
Very high
Significant formal threat
Closure risk
19
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
3
3/19 yrs
Board changes
5
5/19 yrs
PKD changes
3
3/19 yrs
Name changes
0
0/19 yrs
Data from 19 years of registry activity.
Credibility history
Payment reliability score from 2018–2025
Current: E (16/100)
Trend: improving (+7.4 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Trade credit limit history
Standard limit from 2018–2025
Current: 447.2 K PLN
Safe: 44.7 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Medix
Founded
June 15, 2007
19 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
ŁÓDŹ
ŁÓDZKIE
Primary PKD
47.73.Z
Dispensing chemist in specialised stores
Share capital
50.0 K PLN
100 shares total
Shareholders
1
shareholder
Board
3 people
Filed years
8 years
2018–2025 · profitable: 2/8
Registry entries
60
latest: June 26, 2026
Risk signals
Revenue
56.0 M PLN
2025
Net profit
-3.9 M PLN
2025
Assets
39.0 M PLN
2025
Equity
-16.7 M PLN
2025
EBITDA
-1.5 M PLN
2025
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Medix.
No ratings
Related articles
News
Ambra in 2026: PLN 48.1 m capex (+212%), PLN 1.10 dividend three years running, Cydr Lubelski plus Romanian Zarea as the premium engine
Warsaw-based Ambra S.A. (KRS 0000041726, ul. Puławska 336) closed H1 of fiscal 2025/2026 with PLN 556.8 m of revenue and PLN 49.0 m of net profit, while raising capex by 212% to PLN 48.1 m - mainly for the soft-drinks line in Wola Duża and the PLN 11.9 m acquisition of a Romanian company. Despite the aggressive investment cycle the board keeps a PLN 1.10 dividend per share for the third year running (~5.9% yield).
News
Answear in 2026: first full year without MCI, PLN 9.3 m net profit, but the supervisory board cuts the 2026 EBITDA target from PLN 100 m to PLN 90 m
Kraków-based Answear.com S.A. (KRS 0000816066) closed 2025 with revenue of PLN 1.7 bn (+13% YoY), EBITDA of PLN 56 m (+63%) and net profit of PLN 9.3 m - a return to the black after a PLN 10 m loss in 2024. Poland grew +31%, but CEE was under FX pressure (hryvnia -11% vs PLN), and a weak Q4 (EBITDA -71% YoY) forced the supervisory board to cut the 2026 EBITDA target from PLN 100 m to PLN 90 m and the target price from PLN 50 to PLN 45. It is the first full year after MCI's exit from the shareholder base (10 June 2025); the Bajołek brothers retain control (57.8%).
